ACE2 downregulation in olfactory mucosa: Eosinophilic rhinosinusitis as COVID‐19 protective factor?
Concepció Marı́n, Valeria Tubita, Cristóbal Langdon, Mireya Fuentes, María Jesús Rojas‐Lechuga, Antonio Valero, Isam Alobid, Joaquim Mullol
Abstract
Dr. Alobid has consulted for Sanofi, Novartis, GlaxoSmithKline, Menarini, and Mylan. Dr. Mullol has participated in advisory boards for, has received research grants from, or participated in speakers' bureaus for AstraZeneca, Genentech, GlaxoSmithKline, Glenmark, Menarini, Mitsubishi-TanabePharma, MSD, Viatris (Mylan-Meda Pharmaceuticals), Novartis, Procter & Gamble, Regeneron Pharmaceuticals, Inc., Sanofi-Genzyme, UCB Pharma, and UriachGroup. Dr. Marin, Dr. Tubita, Dr. Langdon, M. Fuentes, M.J. Rojas-Lechuga, and Dr. Valero declare that they have no relevant conflict of interest. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.